{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:51:00Z","timestamp":1780404660103,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Brain Tumor Pathol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10014-024-00490-z","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T07:02:19Z","timestamp":1725087739000},"page":"145-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Double-hit primary central nervous system lymphoma with histogenetically proven bone marrow infiltration: a case report and a review of the literature"],"prefix":"10.1007","volume":"41","author":[{"given":"Koki","family":"Onodera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5051-0568","authenticated-orcid":false,"given":"Mitsuaki","family":"Shirahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonari","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsugumi","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"key":"490_CR1","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/bjc.2011.357","volume":"105","author":"JL Villano","year":"2011","unstructured":"Villano JL, Koshy M, Shaikh H et al (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105:1414\u20131418","journal-title":"Br J Cancer"},{"key":"490_CR2","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Neff C et al (2022) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro Oncol 24:v1\u2013v95","journal-title":"Neuro Oncol"},{"key":"490_CR3","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","volume":"36","author":"AJM Ferreri","year":"2022","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E et al (2022) Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia 36:1870\u20131878","journal-title":"Leukemia"},{"key":"490_CR4","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th Edition","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL et al (eds) (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th Edition. IARC, Lyon"},{"key":"490_CR5","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR et al (2022) The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood 140:1229\u20131253","journal-title":"Blood"},{"key":"490_CR6","unstructured":"WHO Classification of Tumours Editorial Board (2022) Haematolymphoid tumours. International Agency for Research on Cancer, Lyon (France). (WHO classification of tumours series, 5th ed; vol 11). [Internet; beta version ahead of print] https:\/\/tumourclassification.iarc.who.int\/chapters\/63. Accessed 4 June 2023"},{"key":"490_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","volume":"37","author":"RK Pillai","year":"2013","unstructured":"Pillai RK, Sathanoori M, Van Oss SB et al (2013) Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol 37:323\u2013332","journal-title":"Am J Surg Pathol"},{"key":"490_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00277-018-3498-z","volume":"98","author":"A Nosrati","year":"2019","unstructured":"Nosrati A, Monabati A, Sadeghipour A et al (2019) MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type. Ann Hematol 98:169\u2013173","journal-title":"Ann Hematol"},{"key":"490_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2020.151610","volume":"48","author":"S Pina-Oviedo","year":"2020","unstructured":"Pina-Oviedo S, Bellamy WT, Gokden M (2020) Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases. Ann Diagn Pathol 48:151610","journal-title":"Ann Diagn Pathol"},{"key":"490_CR10","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1200\/JCO.2008.16.1455","volume":"26","author":"FM Cady","year":"2008","unstructured":"Cady FM, O\u2019Neill BP, Law ME et al (2008) Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 26:4814\u20134819","journal-title":"J Clin Oncol"},{"key":"490_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00401-013-1169-7","volume":"126","author":"A Brunn","year":"2013","unstructured":"Brunn A, Nagel I, Montesinos-Rongen M et al (2013) Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta Neuropathol 126:603\u2013605","journal-title":"Acta Neuropathol"},{"key":"490_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/MOH.0b013e328353bbbd","volume":"19","author":"RC Lindsley","year":"2012","unstructured":"Lindsley RC, LaCasce AS (2012) Biology of double-hit B-cell lymphomas. Curr Opin Hematol 19:299\u2013304","journal-title":"Curr Opin Hematol"},{"key":"490_CR13","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.2012.43.5800","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg JW (2012) Double-hit diffuse large B-cell lymphoma. J Clin Oncol 30:3439\u20133443","journal-title":"J Clin Oncol"},{"key":"490_CR14","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35:2410\u20132418","journal-title":"J Clin Oncol"},{"key":"490_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.25259\/SNI_307_2023","volume":"14","author":"M Parkhi","year":"2023","unstructured":"Parkhi M, Chatterjee D, Radotra BD et al (2023) Double-hit and double-expressor primary central nervous system lymphoma: Experience from North India of an infrequent but aggressive variant. Surg Neurol Int 14:172","journal-title":"Surg Neurol Int"},{"key":"490_CR16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41375-019-0691-6","volume":"34","author":"F Cucco","year":"2020","unstructured":"Cucco F, Barrans S, Sha C et al (2020) Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC\/BCL2 double-hit. Leukemia 34:1329\u20131341","journal-title":"Leukemia"},{"key":"490_CR17","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1007\/s13277-015-4205-5","volume":"37","author":"J Li","year":"2016","unstructured":"Li J, Zhao S, Wang J et al (2016) CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases. Tumour Biol 37:3619\u20133637","journal-title":"Tumour Biol"},{"key":"490_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1479-5876-10-84","volume":"10","author":"YJ Li","year":"2012","unstructured":"Li YJ, Li ZM, Rao HL et al (2012) CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution. J Transl Med 10:84","journal-title":"J Transl Med"},{"key":"490_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175526","volume":"943","author":"SA Setiawan","year":"2023","unstructured":"Setiawan SA, Liu WZ, Weng PW et al (2023) Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma. Eur J Pharmacol 943:175526","journal-title":"Eur J Pharmacol"},{"key":"490_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","volume":"80","author":"K Jahnke","year":"2006","unstructured":"Jahnke K, Thiel E, Martus P et al (2006) Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol 80:159\u2013165","journal-title":"J Neurooncol"},{"key":"490_CR21","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1080\/10428194.2018.1563294","volume":"60","author":"R Malani","year":"2019","unstructured":"Malani R, Bhatia A, Wolfe J et al (2019) Staging identifies non-CNS malignancies in a large cohort with newly diagnosed lymphomatous brain lesions. Leuk Lymphoma 60:2278\u20132282","journal-title":"Leuk Lymphoma"},{"key":"490_CR22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/10428194.2018.1482538","volume":"60","author":"A Brandt","year":"2019","unstructured":"Brandt A, Matschke J, Fehrle W et al (2019) A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells. Leuk Lymphoma 60:334\u2013340","journal-title":"Leuk Lymphoma"},{"key":"490_CR23","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1093\/neuonc\/noab109","volume":"23","author":"M Margold","year":"2021","unstructured":"Margold M, Seidel S, Kowalski T et al (2021) The value of bone marrow biopsy for staging of patients with primary CNS lymphoma. Neuro Oncol 23:2076\u20132084","journal-title":"Neuro Oncol"},{"key":"490_CR24","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00277-023-05282-7","volume":"102","author":"J Jelicic","year":"2023","unstructured":"Jelicic J, Hansen DL, Carlsen SS et al (2023) Bone marrow biopsy can be omitted in the diagnostic workup of CNS lymphoma of DLBCL origin: a population-based retrospective study in the PET-CT era. Ann Hematol 102:1897\u20131905","journal-title":"Ann Hematol"},{"key":"490_CR25","doi-asserted-by":"publisher","first-page":"omad026","DOI":"10.1093\/omcr\/omad026","volume":"2023","author":"NCN Khalil","year":"2023","unstructured":"Khalil NCN, Iwaiwi BI, Hammad S et al (2023) A necrotic primary central nervous system lymphoma in immunocompetent patient with MYC and BCL6 rearrangements (double-hit lymphoma): a case report. Oxf Med Case Rep 2023:omad026","journal-title":"Oxf Med Case Rep"},{"key":"490_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF01054724","volume":"25","author":"BP O\u2019Neill","year":"1995","unstructured":"O\u2019Neill BP, Dinapoli RP, Kurtin PJ et al (1995) Occult systemic non-Hodgkin\u2019s lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough? J Neurooncol 25:67\u201371","journal-title":"J Neurooncol"},{"key":"490_CR27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/(SICI)1097-0142(19960301)77:5<827::AID-CNCR4>3.0.CO;2-B","volume":"77","author":"AJ Ferreri","year":"1996","unstructured":"Ferreri AJ, Reni M, Zoldan MC et al (1996) Importance of complete staging in non-Hodgkin\u2019s lymphoma presenting as a cerebral mass lesion. Cancer 77:827\u2013833","journal-title":"Cancer"},{"key":"490_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1215\/15228517-2007-061","volume":"10","author":"NA Mohile","year":"2008","unstructured":"Mohile NA, Deangelis LM, Abrey LE (2008) The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol 10:223\u2013228","journal-title":"Neuro Oncol"},{"key":"490_CR29","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1007\/s00259-021-05348-6","volume":"48","author":"D Kaddu-Mulindwa","year":"2021","unstructured":"Kaddu-Mulindwa D, Altmann B, Held G et al (2021) FDG PET\/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging 48:3550\u20133559","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"490_CR30","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/ajh.24044","volume":"90","author":"TH Chen-Liang","year":"2015","unstructured":"Chen-Liang TH, Martin-Santos T, Jerez A et al (2015) The role of bone marrow biopsy and FDG-PET\/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients. Am J Hematol 90:686\u2013690","journal-title":"Am J Hematol"}],"container-title":["Brain Tumor Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-024-00490-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10014-024-00490-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-024-00490-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:28:20Z","timestamp":1729700900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10014-024-00490-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":30,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["490"],"URL":"https:\/\/doi.org\/10.1007\/s10014-024-00490-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4216246\/v1","asserted-by":"object"}]},"ISSN":["1433-7398","1861-387X"],"issn-type":[{"value":"1433-7398","type":"print"},{"value":"1861-387X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,31]]},"assertion":[{"value":"4 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and the accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors did not use AI or AI-assisted tools.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}]}}